The primary thought from today's analysis is, don't fight the tape. What does that mean exactly? We've seen some wild swings and you need to be able to adjust quickly. John Carter of Simpler Options looks at a few of his favorite markets for that type of action and how to trade each instance. Is it time to swoop in a buy on weakness or will we restest the lows and move lower? Carter explains that chart work points to a decline into the end of September, possibly to the 1721 level in the S&P. That said, there is the potential to rally to 2013 due to short covering rallies before moving over. Carter is using rallies to set up bearish positions by selling calls or selling S&P futures and shows what indicators and averages he is using on the charts to initiate strategies. This could also be a good time to sell puts on a decline as premiums are elevated in the case of Facebook (FB), for example. You could also play the other side of the tape with premium sales. In a rally, Carter would be looking to sell calls on Google (GOOGL). Directional plays would include buying puts on the SPDR S&P 500 ETF (SPY), shorting the SPX or Nasdaq (NDX). Carter looks at Sucampo Pharmaceuticals (SCMP), which has been holding up pretty well in a choppy tape and would look to sell September 25 puts as Carter would not mind owning the stock at $25. SCMP is sitting above key moving averages which is a bullish for the price action. As the markets move lower, these are the kind of ideas you should be looking for longer-term. Gopro (GPRO), in the other hand, is not a stock Carter is buying and would look to sell on rallies. As you can see on the chart, it is well below the key moving averages Carter uses for his chart work. Finally, Carter reviews the TRIN indicator and what he thinks it is signaling.
More from Video
Jim Cramer's Top Stock Pick to Buy for the 5G Revolution
Skyworks and Qorvo will be big players in providing the tech for the switch to 5G, but neither is Jim's top pick.
Novartis Still a Buy Despite Controversy Over Blockbuster Drug
Despite the issues that have bubbled up related to its breakthrough drug for spinal muscular atrophy, Zolgensma, Novartis "has the newest pipeline with many drugs just beginning to have an impact on the company's bottom line," Cramer told members of his Action Alerts PLUS club for investors during an exclusive video-conference call.
Jim Cramer: Mastercard Is One Thing Money Can Buy
The slogan was: There are some things money can't buy; for everything else, there's Mastercard. Fast forward more than two decades and the world of fintech and digital payment processing has changed, and Mastercard has changed right along with it.
Jim Cramer Picks Twilio as Good Buy Despite Recent Controversy
Despite a recent pair of big mistakes, cloud services provider Twilio's explosive growth still makes it a good buy, Jim Cramer says.
Apple Sees a Big Price Target Raise, But There's One 'X' Factor
Apple's fundamentals are looking better every few weeks, but the trade war is unresolved. And it threatens those positive trending fundamentals.